Print Page     Close Window     

SEC Filings

8-K
SERES THERAPEUTICS, INC. filed this Form 8-K on 10/16/2017
Entire Document
 


Slide 14

Efficacy Analysis: All subjects, missing data counted as failure Endpoint Intent-to-Treat Population: All Subjects, Missing Data Counted as Failure   Placebo / Placebo (N = 11) (%) Vancomycin / SER-287 daily (N = 15) (%) Placebo / SER-287 weekly (N = 15) (%) Vancomycin / SER-287 weekly (N = 17) (%) Clinical Remission: 0/11 (0%) 6/15 (40%) 2/15 (13.3%) 3/17 (17.7%) Difference from placebo (SER-287 minus placebo) 40.0% 13.3%  17.7% p-value 0.0237 0.4923 0.2579 Endoscopic Improvement: 1/11 (9.1%) 6/15 (40%) 5/15 (33.3%) 4/17 (23.5%) Difference from placebo (SER-287 minus placebo) 30.9% 24.2%  14.4% p-value 0.1783 0.1973 0.6195 Clinical Response: 5/11 (45.5%) 9/15 (60%) 6/15 (40%) 4/17 (23.5%) Difference from placebo (SER-287 minus placebo) 14.5% -5.5%  -22.0% p-value 0.6922 0.9999 0.4087


© Seres Therapeutics. All Rights Reserved.